ChemoMetec Raises 2026/27 Guidance, Reports Preliminary Q1 Results
ChemoMetec lifted revenue guidance to DKK 570–605 million from DKK 560–590 million and EBITDA guidance to DKK 335–360 million from DKK 330–345 million. Preliminary Q1 revenue rose 28% year over year to DKK 160.0 million; EBITDA was DKK 100.3 million, a 63% margin.
ChemoMetec A/S announced an upward revision to its financial guidance for the 2026/27 fiscal year, citing higher-than-expected demand for its instruments, particularly the NC-203, and a lower cost base. The company now expects full-year revenue in the range of DKK 570-605 million, up from the previous forecast of DKK 560-590 million. EBITDA guidance has also been increased to DKK 335-360 million, compared to the prior range of DKK 330-345 million. Additionally, the company provided preliminary results for the first quarter of 2026/27, reporting revenue of DKK 160.0 million, a 28% increase year-over-year, and an EBITDA of DKK 100.3 million, representing a 63% margin.